CAMP4 Therapeutics (NASDAQ:CAMP) Stock Rated Outperform in New Coverage at Oppenheimer

Oppenheimer initiated coverage on shares of CAMP4 Therapeutics (NASDAQ:CAMP) in a research report sent to investors on Monday morning, MarketBeat Ratings reports. The firm issued an outperform rating and a $15.00 price target on the Wireless communications provider’s stock.

CAMP has been the topic of several other research reports. JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $5.00 to $9.00 in a research note on Tuesday, June 16th. Piper Sandler restated an “overweight” rating and set a $15.00 price objective (up from $12.00) on shares of CAMP4 Therapeutics in a research report on Friday, August 14th. Cantor Fitzgerald restated an “overweight” rating on shares of CAMP4 Therapeutics in a research report on Tuesday, September 29th. Chardan Capital reduced their price objective on CAMP4 Therapeutics from $6.50 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, September 29th. Finally, Weiss Ratings cut CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 2nd. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $10.86.

CAMP4 Therapeutics Trading Down 3.0%

Shares of CAMP4 Therapeutics stock opened at $3.84 on Monday. The company has a market cap of $240.96 million, a PE ratio of -1.66 and a beta of 0.27. The company has a 50 day moving average of $4.19 and a 200-day moving average of $4.23. CAMP4 Therapeutics has a 1-year low of $2.86 and a 1-year high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its quarterly earnings data on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. The firm had revenue of $1.78 million during the quarter. Research analysts forecast that CAMP4 Therapeutics will post -0.66 earnings per share for the current year.

Insider Activity at CAMP4 Therapeutics

In other CAMP4 Therapeutics news, Director Andrew J. Schwab sold 400,000 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $4.04, for a total value of $1,616,000.00. Following the completion of the transaction, the director directly owned 2,033,270 shares in the company, valued at approximately $8,214,410.80. This represents a 16.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Kelly Gold purchased 10,000 shares of the firm’s stock in a transaction on Monday, August 31st. The stock was acquired at an average price of $3.96 per share, with a total value of $39,600.00. Following the completion of the transaction, the chief financial officer owned 10,000 shares in the company, valued at approximately $39,600. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders acquired 46,031 shares of company stock worth $99,051 and sold 593,613 shares worth $2,504,037. 21.69% of the stock is owned by company insiders.

Hedge Funds Weigh In On CAMP4 Therapeutics

Hedge funds have recently modified their holdings of the business. Jupiter Topco LLC acquired a new stake in CAMP4 Therapeutics in the second quarter valued at $27,581,000. 5AM Venture Management LLC acquired a new position in CAMP4 Therapeutics during the 2nd quarter worth about $25,647,928. Trails Edge Capital Partners LP acquired a new position in CAMP4 Therapeutics during the 2nd quarter worth about $8,446,935. BlackRock Inc. bought a new stake in shares of CAMP4 Therapeutics in the 2nd quarter valued at about $7,185,000. Finally, SummitTX Capital L.P. bought a new stake in shares of CAMP4 Therapeutics in the 1st quarter valued at about $1,497,000.

About CAMP4 Therapeutics

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing RNA-based medicines for genetic diseases caused by insufficient production of essential proteins. The company’s approach is designed to increase expression of a patient’s existing genes rather than replace or edit them.

CAMP4 uses its RegRNA platform to identify regulatory elements in messenger RNA and develop RNA activators, including small activating RNAs, that may stimulate production of targeted proteins.